Cobimetinib Plus Vemurafenib Produces Antitumor Activity in Patients With BRAF Mutations
June 7th 2022Results from a cohort of the TAPUR study showed that the combination of cobimetinib plus vemurafenib demonstrated antitumor activity among patients with BRAF mutations who are not otherwise eligible for treatment with other FDA-approved therapies.
Fixed-Dose Nivolumab Plus Relatlimab Showed Consistent PFS Benefit in Metastatic Melanoma
June 6th 2022A sustained progression-free survival benefit was observed with nivolumab plus relatlimab-rmbw vs nivolumab alone in the phase 2/3 RELATIVITY-047 trial in treatment-naïve, unresectable or metastatic melanoma.
Black Patients with Metastatic Breast Cancer Less Likely to Trust, Participate in Clinical Trials
May 26th 2022A Black patient with metastatic breast cancer explained that the results of the survey show that more work must be done by all stakeholders to increase the participation in clinical trials to accurately assess treatments in diversified populations.
Meric-Bernstam, MD, Discusses Pertuzumab Plus Trastuzumab Use Across HER2-Positive Solid Tumors
August 5th 2021CancerNetwork® sat down with Funda Meric-Bernstam, MD, at the 2021 ASCO Annual Meeting to talk about results of the MyPathway study in HER2-positive advanced solid tumors treated with pertuzumab plus trastuzumab.
Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer
June 8th 2021Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, according to data from the 2021 ASCO Annual Meeting.
Lifileucel Continues to Show Durable Responses in Advanced Melanoma
June 6th 2021With further follow-up, lifileucel (LN-144) continued to show durable responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed on multiple therapies, including prior anti–PD-1/PD-L1 therapy
Nivolumab Monotherapy, With Ipilimumab Continuously Improves Outcomes in Advanced Melanoma
June 6th 2021Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.